Mamoo Nakamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mamoo Nakamura has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Saibal Kar
Los Robles Regional Medical Center, Thousand Oaks, CA (S.K.).
11 shared publications Tarun Chakravarty
Cedars‐Sinai Medical Center, Smidt Heart Institute
10 shared publicationsWen Cheng
The Smidt Heart Institute
9 shared publications- Asma Hussaini
Heart Institute, Cedars Sinai Medical Center, 8631 West 3rd Street, Suite 415E, Los Angeles, CA, 90048, USA
8 shared publications - Raj Makkar
Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (R.M.).
8 shared publications Takashi Nagasaka
Cedars‐Sinai Medical Center, Smidt Heart Institute
8 shared publications
Latest Publications
- 3 November 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (21)
Clinical Impact of Multiple‐Clip Implantation for Residual Mitral Regurgitation After Transcatheter Edge‐to‐Edge Repair
Background: Residual moderate or greater mitral regurgitation (MR) after transcatheter edge‐to‐edge repair is strongly associated with adverse clinical outcomes. However, the prognostic impact of implanting additional clips in patients with significant residual MR after the first clip remains uncertain. We evaluated the clinical and echocardiographic outcomes of multiple‐clip implantation for significant residual MR following placement of the initial clip. Methods: We retrospectively evaluated 826 patients with moderate or greater residual MR on intraprocedural transesophageal echocardiography after placement of the first clip during transcatheter edge‐to‐edge repair at the Cedars‐Sinai Medical Center from 2014 to 2023. Patients were categorized into single‐clip (n=113) and multiple‐clip (n=713) groups. The primary end point was the composite of all‐cause mortality and heart failure hospitalization at 1 year. Results: Procedural technical success and complication rates were comparable between groups. The multiple‐clip group demonstrated greater MR reduction and higher transmitral pressure gradients at discharge, 30 days, and 1 year. At 1 year, the composite end point occurred less frequently in the multiple‐clip group than in the single‐clip group (16.8% versus 29.2%; P =0.002), along with greater and more sustained improvement in New York Heart Association functional class. In subgroup analyses, multiple‐clip implantation consistently reduced major adverse cardiovascular events in patients with moderate as well as moderate–severe/severe residual MR. Conclusions: In patients with significant residual MR after implanting the first clip, multiple‐clip implantation improved MR reduction and 1‐year outcomes without increasing complications. Even in moderate residual MR, additional clips were associated with more favorable clinical outcomes.
- 3 November 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (21)
Clinical Impact of Multiple‐Clip Implantation for Residual Mitral Regurgitation After Transcatheter Edge‐to‐Edge Repair
Background: Residual moderate or greater mitral regurgitation (MR) after transcatheter edge‐to‐edge repair is strongly associated with adverse clinical outcomes. However, the prognostic impact of implanting additional clips in patients with significant residual MR after the first clip remains uncertain. We evaluated the clinical and echocardiographic outcomes of multiple‐clip implantation for significant residual MR following placement of the initial clip. Methods: We retrospectively evaluated 826 patients with moderate or greater residual MR on intraprocedural transesophageal echocardiography after placement of the first clip during transcatheter edge‐to‐edge repair at the Cedars‐Sinai Medical Center from 2014 to 2023. Patients were categorized into single‐clip (n=113) and multiple‐clip (n=713) groups. The primary end point was the composite of all‐cause mortality and heart failure hospitalization at 1 year. Results: Procedural technical success and complication rates were comparable between groups. The multiple‐clip group demonstrated greater MR reduction and higher transmitral pressure gradients at discharge, 30 days, and 1 year. At 1 year, the composite end point occurred less frequently in the multiple‐clip group than in the single‐clip group (16.8% versus 29.2%; P =0.002), along with greater and more sustained improvement in New York Heart Association functional class. In subgroup analyses, multiple‐clip implantation consistently reduced major adverse cardiovascular events in patients with moderate as well as moderate–severe/severe residual MR. Conclusions: In patients with significant residual MR after implanting the first clip, multiple‐clip implantation improved MR reduction and 1‐year outcomes without increasing complications. Even in moderate residual MR, additional clips were associated with more favorable clinical outcomes.
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (17)
Mitral Transcatheter Edge‐to‐Edge Repair in Younger Adults
Background: Younger patients aged ≤65 years who have significant comorbidities deemed unsuitable for surgery, transcatheter edge‐to‐edge repair (TEER) may serve as an alternative, although the long‐term outcomes remain uncertain. This study aimed to compare clinical outcomes after TEER between younger patients (aged ≤65 years) and elderly patients (aged >65 years). Methods: A retrospective analysis was performed on 1364 consecutive patients with mitral regurgitation. The primary end point was 3‐year all‐cause mortality. Optimal device success was defined as achieving mild or less residual mitral regurgitation and less than 5 mm Hg transmitral mean gradient. Results: In the current cohort, 247 patients (18.1%) were younger than 65 years (median age: 58 years; interquartile ranges: 52–62), with 62.8% being men. Those younger patients had lower left ventricular ejection functions and were more likely to have secondary mitral regurgitation, congestive heart failure. Despite a higher‐risk clinical profile, composite of all‐cause mortality, heart failure hospitalization, or reintervention after TEER were comparable between younger and older patients. Younger patients demonstrated significantly lower 3‐year all‐cause mortality compared with older patients (18.5% versus 30.3%, P =0.007). Younger patients with device success had the lowest mortality compared with elderly patients with unsuccessful procedures (13.9% versus 34.3%, P =0.001). Among patients with unsuccessful procedures, TEER did not improve outcomes in younger patients compared with older patients. Propensity‐matched analysis confirmed that younger patients continued to demonstrate lower 3‐year all‐cause mortality (18.5% versus 34%, P =0.034). Conclusions: Younger mitral regurgitation patients undergoing TEER had more advanced congestive heart failure but lower 3‐year mortality than elderly patients. However, those without optimal device success showed no survival benefit over their older counterparts, underscoring the need for close follow‐up and consideration of timely reintervention.
- 1 September 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (17)
Open AccessMitral Transcatheter Edge‐to‐Edge Repair in Younger Adults
Background: Younger patients aged ≤65 years who have significant comorbidities deemed unsuitable for surgery, transcatheter edge‐to‐edge repair (TEER) may serve as an alternative, although the long‐term outcomes remain uncertain. This study aimed to compare clinical outcomes after TEER between younger patients (aged ≤65 years) and elderly patients (aged >65 years). Methods: A retrospective analysis was performed on 1364 consecutive patients with mitral regurgitation. The primary end point was 3‐year all‐cause mortality. Optimal device success was defined as achieving mild or less residual mitral regurgitation and less than 5 mm Hg transmitral mean gradient. Results: In the current cohort, 247 patients (18.1%) were younger than 65 years (median age: 58 years; interquartile ranges: 52–62), with 62.8% being men. Those younger patients had lower left ventricular ejection functions and were more likely to have secondary mitral regurgitation, congestive heart failure. Despite a higher‐risk clinical profile, composite of all‐cause mortality, heart failure hospitalization, or reintervention after TEER were comparable between younger and older patients. Younger patients demonstrated significantly lower 3‐year all‐cause mortality compared with older patients (18.5% versus 30.3%, P =0.007). Younger patients with device success had the lowest mortality compared with elderly patients with unsuccessful procedures (13.9% versus 34.3%, P =0.001). Among patients with unsuccessful procedures, TEER did not improve outcomes in younger patients compared with older patients. Propensity‐matched analysis confirmed that younger patients continued to demonstrate lower 3‐year all‐cause mortality (18.5% versus 34%, P =0.034). Conclusions: Younger mitral regurgitation patients undergoing TEER had more advanced congestive heart failure but lower 3‐year mortality than elderly patients. However, those without optimal device success showed no survival benefit over their older counterparts, underscoring the need for close follow‐up and consideration of timely reintervention.
- Open Access
- 3 February 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (3) , e043880
Comparing Clinical Outcomes of Patients With a Small Versus Large Annulus After Newer‐Generation Balloon‐Expandable Transcatheter Aortic Valve Replacement
Background: Limited data are available comparing clinical outcomes between patients with small and large annuli following transcatheter aortic valve replacement using balloon‐expandable valves. This study sought to investigate 5‐year clinical outcomes in patients with severe aortic stenosis with a small annulus compared with those with a large annulus following transcatheter aortic valve replacement with newer‐generation balloon‐expandable valves. Methods: A total of 3182 patients with aortic stenosis treated with balloon‐expandable valves were divided into small‐annulus (≤430 mm 2 ) and large‐annulus (>430 mm 2 ) groups. A 1:1 propensity‐matched analysis was performed to adjust baseline differences. The primary end point was all‐cause death at 5‐year follow‐up. Secondary end points included heart failure hospitalization, bioprosthetic valve failure, and aortic valve reintervention. Results: Among 533 matched pairs, compared with the large‐annulus group, the small‐annulus group had higher rates of aortic valve mean gradients ≥20 mm Hg (14.1% versus 2.9%; P P =0.019). At 5 years, there were no significant differences in all‐cause death (hazard ratio, 0.75 [95% CI, 0.52–1.09]; P =0.13). The incidence of heart failure rehospitalization, bioprosthetic valve failure, and aortic valve reintervention were similar between groups. Both groups achieved similar sustained improvements in New York Heart Association functional class and Kansas City Cardiomyopathy Questionnaire–Overall Summary scores. Conclusions: Despite higher transvalvular gradients and a greater rate of severe prosthesis–patient mismatch, 5‐year clinical outcomes in patients with a small annulus were comparable to those with a large annulus following transcatheter aortic valve replacement using newer‐generation balloon‐expandable valves.
- 3 February 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (3) , e043880
Open AccessComparing Clinical Outcomes of Patients With a Small Versus Large Annulus After Newer‐Generation Balloon‐Expandable Transcatheter Aortic Valve Replacement
Background: Limited data are available comparing clinical outcomes between patients with small and large annuli following transcatheter aortic valve replacement using balloon‐expandable valves. This study sought to investigate 5‐year clinical outcomes in patients with severe aortic stenosis with a small annulus compared with those with a large annulus following transcatheter aortic valve replacement with newer‐generation balloon‐expandable valves. Methods: A total of 3182 patients with aortic stenosis treated with balloon‐expandable valves were divided into small‐annulus (≤430 mm 2 ) and large‐annulus (>430 mm 2 ) groups. A 1:1 propensity‐matched analysis was performed to adjust baseline differences. The primary end point was all‐cause death at 5‐year follow‐up. Secondary end points included heart failure hospitalization, bioprosthetic valve failure, and aortic valve reintervention. Results: Among 533 matched pairs, compared with the large‐annulus group, the small‐annulus group had higher rates of aortic valve mean gradients ≥20 mm Hg (14.1% versus 2.9%; P P =0.019). At 5 years, there were no significant differences in all‐cause death (hazard ratio, 0.75 [95% CI, 0.52–1.09]; P =0.13). The incidence of heart failure rehospitalization, bioprosthetic valve failure, and aortic valve reintervention were similar between groups. Both groups achieved similar sustained improvements in New York Heart Association functional class and Kansas City Cardiomyopathy Questionnaire–Overall Summary scores. Conclusions: Despite higher transvalvular gradients and a greater rate of severe prosthesis–patient mismatch, 5‐year clinical outcomes in patients with a small annulus were comparable to those with a large annulus following transcatheter aortic valve replacement using newer‐generation balloon‐expandable valves.
- Open Access
- 6 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (1) , e045417
Long‐Term Clinical Outcomes of Balloon‐Expandable Versus Self‐Expanding Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annulus
Background: Self‐expanding valves (SEVs) have demonstrated superior hemodynamic performance and comparable clinical outcomes to balloon‐expandable valves (BEVs) at 1 year in patients with a small aortic annulus. However, long‐term data are limited. This study aimed to evaluate 5‐year echocardiographic and clinical outcomes of SEVs versus BEVs in patients with small aortic annulus underwent transcatheter aortic valve replacement. Methods: We analyzed RESOLVE registry patients who underwent transcatheter aortic valve replacement at Cedars‐Sinai between 2015 and 2020. Patients with a small aortic annulus (2 by computed tomography) were included and followed for up to 5 years. The primary outcome was a composite of all‐cause mortality, stroke, or heart failure hospitalization. Secondary outcomes included myocardial infarction, pacemaker implantation, aortic valve reintervention, and structural bioprosthetic valve dysfunction. Results: Among 1392 transcatheter aortic valve replacement recipients, 423 (78 SEVs, 345 BEVs) met the small annulus criteria. SEVs were associated with lower transvalvular gradients and larger indexed effective orifice area at discharge and 1 year ( P P P P <0.33). All‐cause mortality, stroke, heart failure hospitalization, structural bioprosthetic valve dysfunction, and reintervention rates were similar between groups. Conclusion: Although SEVs provide better hemodynamic performance in patients with severe aortic stenosis and small annuli, this advantage did not translate into improved survival or reduced cardiovascular events at 5 years.
- 6 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (1) , e045417
Open AccessLong‐Term Clinical Outcomes of Balloon‐Expandable Versus Self‐Expanding Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annulus
Background: Self‐expanding valves (SEVs) have demonstrated superior hemodynamic performance and comparable clinical outcomes to balloon‐expandable valves (BEVs) at 1 year in patients with a small aortic annulus. However, long‐term data are limited. This study aimed to evaluate 5‐year echocardiographic and clinical outcomes of SEVs versus BEVs in patients with small aortic annulus underwent transcatheter aortic valve replacement. Methods: We analyzed RESOLVE registry patients who underwent transcatheter aortic valve replacement at Cedars‐Sinai between 2015 and 2020. Patients with a small aortic annulus (2 by computed tomography) were included and followed for up to 5 years. The primary outcome was a composite of all‐cause mortality, stroke, or heart failure hospitalization. Secondary outcomes included myocardial infarction, pacemaker implantation, aortic valve reintervention, and structural bioprosthetic valve dysfunction. Results: Among 1392 transcatheter aortic valve replacement recipients, 423 (78 SEVs, 345 BEVs) met the small annulus criteria. SEVs were associated with lower transvalvular gradients and larger indexed effective orifice area at discharge and 1 year ( P P P P <0.33). All‐cause mortality, stroke, heart failure hospitalization, structural bioprosthetic valve dysfunction, and reintervention rates were similar between groups. Conclusion: Although SEVs provide better hemodynamic performance in patients with severe aortic stenosis and small annuli, this advantage did not translate into improved survival or reduced cardiovascular events at 5 years.
- Open Access
- 15 December 2025
- Published by Springer Nature in Cardiovascular Intervention and Therapeutics
- Vol. 41 (2) , 414-424
One-year outcomes of the RESILIA balloon-expandable transcatheter valve: survival, hemodynamics, and hypoattenuated leaflet thickening
Performance evaluation of the latest fifth-generation SAPIEN 3 Ultra RESILIA (S3UR) valve in patients who underwent transcatheter aortic valve replacement (TAVR) is limited. The aim of this study was to compare the 1-year clinical outcomes, including valve performance, in patients undergoing TAVR with the S3UR compared to the SAPIEN 3 or SAPIEN 3 Ultra (S3/S3U). Patients with severe native aortic stenosis who underwent TAVR with either the S3UR or the S3/S3U valve were matched using propensity scores. Predictors of 1-year outcomes were identified. A subgroup analysis of patients who underwent post-TAVR CT was conducted. Among 4,908 patients, 312 matched pairs were assessed. At 1-year, compared to the S3/S3U group, the S3UR group exhibited lower all-cause mortality (HR: 0.42; 95% CI: 0.18–0.96; p = 0.041). The S3UR group demonstrated superior hemodynamic performance, including lower transvalvular gradients, larger effective orifice areas, and decreased incidence of severe prosthesis-patient mismatch and paravalvular leak. In patients who underwent post-TAVR CT (n = 280), prevalence of hypoattenuated leaflet thickening (HALT) at 30-day was lower in the S3UR group compared to S3/S3U (5.7% vs 16.2%; p = 0.006). In multivariate analysis, the S3UR group was independently associated with lower 1-year mortality and reduced HALT. In this propensity score-matched cohort, compared with the S3/S3U group, the S3UR group demonstrated favorable clinical outcomes and superior hemodynamic performance. In subgroup analysis, S3UR was also associated with a lower HALT incidence. Graphical abstract
- 15 December 2025
- Published by Springer Nature in Cardiovascular Intervention and Therapeutics
- Vol. 41 (2) , 414-424
Open AccessOne-year outcomes of the RESILIA balloon-expandable transcatheter valve: survival, hemodynamics, and hypoattenuated leaflet thickening
Performance evaluation of the latest fifth-generation SAPIEN 3 Ultra RESILIA (S3UR) valve in patients who underwent transcatheter aortic valve replacement (TAVR) is limited. The aim of this study was to compare the 1-year clinical outcomes, including valve performance, in patients undergoing TAVR with the S3UR compared to the SAPIEN 3 or SAPIEN 3 Ultra (S3/S3U). Patients with severe native aortic stenosis who underwent TAVR with either the S3UR or the S3/S3U valve were matched using propensity scores. Predictors of 1-year outcomes were identified. A subgroup analysis of patients who underwent post-TAVR CT was conducted. Among 4,908 patients, 312 matched pairs were assessed. At 1-year, compared to the S3/S3U group, the S3UR group exhibited lower all-cause mortality (HR: 0.42; 95% CI: 0.18–0.96; p = 0.041). The S3UR group demonstrated superior hemodynamic performance, including lower transvalvular gradients, larger effective orifice areas, and decreased incidence of severe prosthesis-patient mismatch and paravalvular leak. In patients who underwent post-TAVR CT (n = 280), prevalence of hypoattenuated leaflet thickening (HALT) at 30-day was lower in the S3UR group compared to S3/S3U (5.7% vs 16.2%; p = 0.006). In multivariate analysis, the S3UR group was independently associated with lower 1-year mortality and reduced HALT. In this propensity score-matched cohort, compared with the S3/S3U group, the S3UR group demonstrated favorable clinical outcomes and superior hemodynamic performance. In subgroup analysis, S3UR was also associated with a lower HALT incidence. Graphical abstract
- 23 June 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (12) , 1512-1523
Prosthesis-Patient Mismatch in Young and Low-Risk Patients After Newer Generation Balloon-Expandable Transcatheter Aortic Valve Replacement
- 23 June 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (12) , 1512-1523
Prosthesis-Patient Mismatch in Young and Low-Risk Patients After Newer Generation Balloon-Expandable Transcatheter Aortic Valve Replacement
- Open Access
- 18 February 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (4) , e037168
Age‐Related Outcomes of Valve‐in‐Valve Transcatheter Aortic Valve Replacement for Structural Valve Deterioration
Background: Valve‐in‐valve transcatheter aortic valve replacement (TAVR) is a recognized alternative for treating the structural valve deterioration of bioprosthetic valves. Recent guidelines and trials have expanded the indications for TAVR to include younger patients with structural valve deterioration. In this study, we aimed to examine the outcomes of valve‐in‐valve TAVR across different age groups to understand the age‐related clinical outcomes of treating structural valve deterioration following surgical aortic valve replacement and TAVR. Methods and Results: In this retrospective study, we included patients who underwent valve‐in‐valve TAVR at our center. We compared procedural complications and clinical outcomes among patients 85 years of age, no significant differences in the incidence of stroke/transient ischemic attack were observed among age groups. All groups exhibited significant improvements in valve hemodynamics that persisted for 3 years. Although leaflet thrombosis assessed using computed tomography imaging 30 days post‐TAVR was more prevalent in the older group, age was not an independent predictor of this outcome. Conclusions: Valve‐in‐valve TAVR was associated with an increased 3‐year mortality risk among older patients despite consistent hemodynamic benefits across all age groups. Age‐related differences in leaflet thrombosis did not predict hypoattenuated leaflet thickening, indicating that further studies are necessary to elucidate its implications.
- 18 February 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (4) , e037168
Open AccessAge‐Related Outcomes of Valve‐in‐Valve Transcatheter Aortic Valve Replacement for Structural Valve Deterioration
Background: Valve‐in‐valve transcatheter aortic valve replacement (TAVR) is a recognized alternative for treating the structural valve deterioration of bioprosthetic valves. Recent guidelines and trials have expanded the indications for TAVR to include younger patients with structural valve deterioration. In this study, we aimed to examine the outcomes of valve‐in‐valve TAVR across different age groups to understand the age‐related clinical outcomes of treating structural valve deterioration following surgical aortic valve replacement and TAVR. Methods and Results: In this retrospective study, we included patients who underwent valve‐in‐valve TAVR at our center. We compared procedural complications and clinical outcomes among patients 85 years of age, no significant differences in the incidence of stroke/transient ischemic attack were observed among age groups. All groups exhibited significant improvements in valve hemodynamics that persisted for 3 years. Although leaflet thrombosis assessed using computed tomography imaging 30 days post‐TAVR was more prevalent in the older group, age was not an independent predictor of this outcome. Conclusions: Valve‐in‐valve TAVR was associated with an increased 3‐year mortality risk among older patients despite consistent hemodynamic benefits across all age groups. Age‐related differences in leaflet thrombosis did not predict hypoattenuated leaflet thickening, indicating that further studies are necessary to elucidate its implications.
- Open Access
- 1 February 2025
- Published by AME Publishing Company in Cardiovascular Diagnosis and Therapy
- Vol. 15 (1) , 28-31
Intraprocedural mitral regurgitation and gradient: key determinants of transcatheter edge-to-edge repair outcomes for primary mitral regurgitation
Intraprocedural mitral regurgitation and gradient: key determinants of transcatheter edge-to-edge repair outcomes for primary mitral regurgitation
- 1 February 2025
- Published by AME Publishing Company in Cardiovascular Diagnosis and Therapy
- Vol. 15 (1) , 28-31
Open AccessIntraprocedural mitral regurgitation and gradient: key determinants of transcatheter edge-to-edge repair outcomes for primary mitral regurgitation
Intraprocedural mitral regurgitation and gradient: key determinants of transcatheter edge-to-edge repair outcomes for primary mitral regurgitation
- 5 June 2024
- Published by Elsevier in The American Journal of Cardiology
- Vol. 224, 46-54
Two-Year Clinical Outcomes of Staged Transcatheter Mitral Edge-to-Edge Repair After Transcatheter Aortic Valve Replacement
- 5 June 2024
- Published by Elsevier in The American Journal of Cardiology
- Vol. 224, 46-54
Two-Year Clinical Outcomes of Staged Transcatheter Mitral Edge-to-Edge Repair After Transcatheter Aortic Valve Replacement
- Open Access
Two-year clinical outcomes of staged transcatheter mitral edge-to-edge repair after transcatheter aortic valve replacement
Background: Residual significant mitral regurgitation (MR) can increase the risk of adverse events following transcatheter aortic valve replacement (TAVR). The clinical benefits of staged transcatheter edge-to-edge repair (TEER) post-TAVR remain underexplored. This study aimed to investigate clinical outcomes of staged TEER for residual significant MR post-TAVR. Methods: This observational study included 314 consecutive patients with chronic residual grade 3+ or 4+ MR at 30 days follow-up post-TAVR, with 104 (33.1%) treated with staged TEER (TEER group) and 210 (66.9%) with medical therapy alone (MT group). The primary composite outcomes were all-cause mortality and heart failure (HF) hospitalization at 2 years. Additional analysis, including changes in MR grade and the New York Association (NYHA) functional classification, and subgroup outcome comparisons based on MR etiology were also conducted. Results: The rate of primary composite outcome was lower in the TEER group than that in the MT group (33.7% vs. 48.1%, p = 0.015). Significant improvement in MR grade and NYHA class was observed in the TEER group after 2 years. Subgroup analysis demonstrated that, among patients with degenerative MR, a lower incidence of composite outcome and HF hospitalization was observed in the TEER group (hazard ratio: 0.35; 95% confidence interval: 0.23?0.53, p < 0.001). Conclusions: Staged TEER post-TAVR was associated with reduced MR and improved clinical outcomes. The clinical significance of MR post-TAVR should be carefully evaluated, and TEER should be considered for patients with significant residual MR, particularly those with degenerative MR.
Open AccessTwo-year clinical outcomes of staged transcatheter mitral edge-to-edge repair after transcatheter aortic valve replacement
Background: Residual significant mitral regurgitation (MR) can increase the risk of adverse events following transcatheter aortic valve replacement (TAVR). The clinical benefits of staged transcatheter edge-to-edge repair (TEER) post-TAVR remain underexplored. This study aimed to investigate clinical outcomes of staged TEER for residual significant MR post-TAVR. Methods: This observational study included 314 consecutive patients with chronic residual grade 3+ or 4+ MR at 30 days follow-up post-TAVR, with 104 (33.1%) treated with staged TEER (TEER group) and 210 (66.9%) with medical therapy alone (MT group). The primary composite outcomes were all-cause mortality and heart failure (HF) hospitalization at 2 years. Additional analysis, including changes in MR grade and the New York Association (NYHA) functional classification, and subgroup outcome comparisons based on MR etiology were also conducted. Results: The rate of primary composite outcome was lower in the TEER group than that in the MT group (33.7% vs. 48.1%, p = 0.015). Significant improvement in MR grade and NYHA class was observed in the TEER group after 2 years. Subgroup analysis demonstrated that, among patients with degenerative MR, a lower incidence of composite outcome and HF hospitalization was observed in the TEER group (hazard ratio: 0.35; 95% confidence interval: 0.23?0.53, p < 0.001). Conclusions: Staged TEER post-TAVR was associated with reduced MR and improved clinical outcomes. The clinical significance of MR post-TAVR should be carefully evaluated, and TEER should be considered for patients with significant residual MR, particularly those with degenerative MR.